The trail enrolled 123 patients at 23 sites across the US and Europe.

Jupiter Endovascular announced that it completed patient enrollment in the SPIRARE II pivotal clinical trial evaluating its Vertex system.

“In these first cases, the Vertex system was successful in safely navigating through the right heart and into the pulmonary vasculature, facilitating an efficient and effective pulmonary embolectomy ...

The ALPHA-PE Research Fund is designed to support physician-led studies that advance understanding of pulmonary embolism and ...

Pulmonary embolism (PE) is a common and potentially life-threatening condition with presentations ranging from mild symptoms to circulatory collapse. Early and accurate risk stratification is ...

AngioDynamics, Inc. and The PERT Consortium announced the launch of the ALPHA-PE Research Fund, an investigator-led initiative ...

Please provide your email address to receive an email when new articles are posted on . As catheter-directed therapies have advanced in recent years, they are becoming a critical part of the strategy ...

Approximately one in six patients hospitalized for a first episode of syncope have a pulmonary embolism, a new study shows, with the prevalence of pulmonary embolism highest among individuals without ...

THE rationale for venous ligation in pulmonary embolic disease is based on its assumed ability to prevent subsequent emboli from reaching the lungs. The level of the inferior vena cava is now ...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options ...